Evidence map›Paper›PMID 27863423›Full record

ArticleOncotarget2016

Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.

Michael John Sax, Christin Gasch, Vineel Rag Athota, Ruth Freeman, Parisa Rasighaemi, David Elton Westcott, Christopher John Day, Iva Nikolic, Benjamin Elsworth, Ming Wei and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Single-cell dissection of pleural and systemic immunity uncovers pathogen-specific immune reprogramming in tuberculosis versus lung adenocarcinoma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Immune mediated support of metastasis: Implication for bone invasion.Cancer communications (London, England) · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Michael John SaxSchool of Medical Science, Griffith University, Gold Coast, QLD, Australia.
Christin GaschSchool of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
Vineel Rag AthotaSchool of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
Ruth FreemanSchool of Medical Science, Griffith University, Gold Coast, QLD, Australia.
Parisa RasighaemiSchool of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
David Elton WestcottSchool of Medicine, Western Sydney University, Campbelltown NSW, Australia.
Christopher John DayGlycomics Institute, Griffith University, Gold Coast, QLD, Australia.
Iva NikolicKinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Benjamin ElsworthKinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Ming WeiSchool of Medical Science, Griffith University, Gold Coast, QLD, Australia.
Kelly RogersCentre for Dynamic Imaging, Walter and Eliza Hall Institute for Medical Research, Parkville Victoria, Australia.
Alexander SwarbrickKinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Vivek MittalCardiothoracic Surgery and Neuberger Berman Lung Cancer Centre, Weill Cornell Medical College, New York, NY, USA.
Normand PouliotMatrix Microenvironment & Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.
Albert Sleiman MellickSchool of Medical Science, Griffith University, Gold Coast, QLD, Australia.
Griffith University · AUDeakin University · AUCamden and Campbelltown Hospitals · AUCornell University · USGarvan Institute of Medical Research · AUIngham Institute · AULa Trobe University · AUSt Vincent's Clinic · AUUNSW Sydney · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has recently been suggested that the chemokine receptor (CCR5) is required for bone marrow (BM) derived endothelial progenitor cell (EPC) mediated angiogenesis. Here we show that suppression of either cancer cell produced CCL5, or host CCR5 leads to distinctive vascular and tumor growth defects in breast cancer. Surprisingly, CCR5 restoration in the BM alone was not sufficient to rescue the wild type phenotype, suggesting that impaired tumor growth associated with inhibiting CCL5/CCR5 is not due to defects in EPC biology. Instead, to promote angiogenesis cancer cell CCL5 may signal directly to endothelium in the tumor-stroma. In support of this hypothesis, we have also shown: (i) that endothelial cell CCR5 levels increases in response to tumor-conditioned media; (ii) that the amount of CCR5+ tumor vasculature correlates with invasive grade; and (iii) that inhibition of CCL5/CCR5 signaling impairs endothelial cell migration, associated with a decrease in activation of mTOR/AKT pathway members. Finally, we show that treatment with CCR5 antagonist results in less vasculature, impaired tumor growth, reduced metastases and improved survival. Taken as a whole, this work demonstrates that directly inhibiting CCR5 expressing vasculature constitutes a novel strategy for inhibiting angiogenesis and blocking metastatic progression in breast cancer.

Indexed as

Neovascularization, PathologicAngiogenesis InhibitorsAnimalsBreast NeoplasmsCCR5 Receptor AntagonistsCell Line, TumorCell MovementCell ProliferationChemokine CCL5Culture Media, ConditionedCyclohexanesEndothelial CellsFemaleHumansMaravirocMice, Inbred BALB CAngiogenesis InhibitorsCCL5 protein, humanCcl5 protein, mouseCCR5 protein, humanCCR5 protein, mouseCCR5 Receptor AntagonistsChemokine CCL5Culture Media, ConditionedCyclohexanesMaravirocMTOR protein, humanProto-Oncogene Proteins c-aktReceptors, CCR5TOR Serine-Threonine KinasesTriazolesangiogenesisbreast cancerCCL5CCR5shRNAi

Identifiers

PMID27863423
PMCPMC5356747
OpenAlexW2553473081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.